PARSIPPANY, N.J., April 2, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a market leader in healthcare product commercialization and integrated marketing services, has hired Greg Richard as General Manager for its Interpace Diagnostics subsidiary. Richard will be responsible for evolving and driving the execution of PDI's molecular diagnostics growth strategy.
"Molecular Diagnostics is a fast-growing market that represents a significant opportunity for PDI," said Nancy Lurker, chief executive officer of PDI, Inc. "Greg's dynamic experience in developing strategy, driving revenue growth and his relationships with payers in molecular diagnostics is exactly what we sought to help PDI execute our long term strategic vision."
Mr. Richard has more than 20 years of successful experience in sales, marketing and managed care with life science companies ranging from Fortune 500 to small, privately held organizations. He joins PDI from Strata Pathology Services, where he restructured and grew the anatomical pathology sales organization and worked to expand the Company's geographic presence.
He was previously Executive Vice President of Sales and Marketing at Signal Genetics, a New York-based start-up molecular diagnostics company, where he built a new sales team and launched the company's two proprietary molecular oncology tests. Earlier in his career, Richard was Northeast Vice President of Sales for LabCorp, with responsibility for physician sales of the company's routine and molecular diagnostics (esoteric) testing services and a team of 150 reps with $1 billion in revenues, and spent eight years with Quest Diagnostics where he reached the level of Vice President, Health Plan and Payor Markets.Mr. Richard will oversee Interpace Diagnostics' operations, business development, sales and marketing functions. His responsibilities include the identification and establishment of new molecular diagnostics commercialization partnerships and managed care strategy development, and he will be a member of PDI's Executive Committee.